Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2005-04-08
2011-12-13
Wang, Chang-Yu (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C514S001100, C514S001200, C514S001300
Reexamination Certificate
active
08076449
ABSTRACT:
The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a neurodegenerative disease, comprising the following polypeptide shown in any of (a) to (c): (a) a polypeptide comprising the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); (b) a polypeptide comprising an amino acid sequence having a deletion, substitution, insertion, and/or addition of one or several amino acids in the amino acid sequence consisting of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death associated with neurodegenerative disease; and (c) a modified polypeptide from the polypeptide (a) or (b), or a pharmaceutically acceptable salt thereof, as an effective ingredient.
REFERENCES:
patent: 6174862 (2001-01-01), Brenneman
patent: 6613740 (2003-09-01), Gozes et al.
patent: 7314864 (2008-01-01), Nishimoto
patent: 2005/0233413 (2005-10-01), Nishimoto et al.
patent: 2008/0102055 (2008-05-01), Chiba et al.
patent: 2009/0075900 (2009-03-01), Aiso et al.
patent: 1221480 (2001-03-01), None
patent: 2001-522228 (2001-11-01), None
patent: WO-00/53217 (2000-09-01), None
patent: WO-01/12654 (2001-02-01), None
patent: WO-01/21787 (2001-03-01), None
patent: WO-01/92333 (2001-12-01), None
patent: WO-03/097687 (2003-11-01), None
patent: WO-2004/060309 (2004-07-01), None
patent: WO-2004/080957 (2004-09-01), None
Burgess et al. J of Cell Bio. 1990, 111:2129-2138.
Bowie et al. Science, 1990, 247:1306-1310.
Pawson et al. 2003, Science 300:445-452.
Chiba, T. et al., “Development of a Femtomolar-Acting Humanin Derivative Named Colivelin by Attaching Activity-Dependent Neurotrophic Factor to Its N Terminus: Characterization of Colivelin-Mediated Neuroprotection against Alzheimer's Disease-Relevant Insults in Vitro and in Vivo,” The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, vol. 25, No. 44, pp. 10252-10261, Nov. 2, 2005, XP-002532185.
Supplementary Partial European Search Report for corresponding European Application No. 05730322.4 mailed Jun. 29, 2009.
Don W. Cleveland et al.,Neuroscience, vol. 2, (Nov. 2001), pp. 806819.
Collette K. Hand, PhD. et al.,Muscle&Nerve, (Feb. 2002), pp. 135-159.
Lewis P. Rowland, M.D, et al.,The New England Journal of Medicine, vol. 344, No. 22, (May 31, 2001), pp. 1688-1701.
Martin R. Turner et al.,Seminars in Neurology,vol. 21, No. 2, (2001), pp. 167-175.
Robert G. Miller, M.D. at al.,Annals of Neurology, vol. 39, No. 2, (Feb. 1996), pp. 256-0261.
Daniel R. Rosen et al.,Nature, vol. 362, (Mar. 4, 1993), 59-62.
Shahrooz Rabizadeh et al.,Proc. Natl. Acad. Sci., vol. 92, (Mar. 1995), pp. 3024-3028.
H.D. Durham, PhD. et al.,Journal of Neuropathology and Experimental Neurology, vol. 56, No. 5, (May 1997), pp. 523-530.
C.D. Ghadge et al.,The Journal of Neuroscience, vol. 17, No. 22, (Nov. 15, 1997), pp. 8756-8766.
Vladimir Kostic et al.,Science, vol. 277, (Jul. 25, 1997), pp. 559-562.
Mimoun Azzouz et al.,Human Molecular Genetics, vol. 9, No. 5, (2000), pp. 803-811.
Mingwei Li et al.,Science, vol. 288, (Apr. 14, 2000), pp. 335-339.
Kohsuke Kanekura et al,The Journal of Biological Chemistry, vol. 279, No. 18, (Apr. 30, 2004), pp. 19247-19256.
Barkur S. Shastry et al.,Brain Research Bulletin, vol. 48, No. 2, (1999), pp. 121-127.
B. Zhao et al.,Journal of Neuroscience Research, vol. 47, (1997), pp. 253-263.
Jin-Jun Luo et al,Journal of Neuroscience Research, vol. 55, (1999), pp. 629-642.
Benjamin Wolozin et al.,Science, vol. 274, (Dec. 6, 1996), pp. 1710-1713.
Wolozin et al.,Neurobiology of Aging, vol. 19, No. 15, (1998), pp. S23-S27.
Qing Guo et al.,NeuroReport,vol. 8, (1996), pp. 379-383.
Zhuohua Zhang et al.,Nature, vol. 395, (Oct. 15, 1998), pp. 698-702.
Qing Guo et al.,Proc. Natl. Acad. Sci. USA, vol. 96, (Mar. 1999),pp. 4125-4130.
C. Chech et al.,Neuroscience, vol. 87, No. 2, (1998), pp. 325-336.
Conrad C. Weihl et al.,The Journal of Neuroscience,vol. 19, No. 13, (Jul. 1, 1999), pp. 5360-5369.
Sherry Bursztajn et al.,The Journal of Neuroscience, vol. 18, No. 23, (Dec. 1, 1998), pp. 9790-9799.
T. Yamatsuji et al.,Science, vol. 272, (1996), pp. 1349-1352.
Hashimoto et. al., The Jornal of Neuroscience vol. 21, No. 23, pp. 9235-9245 (Dec. 1, 2001).
Terashita et al., Journal of Neurochemistry vol. 85, pp. 1521-1538 (2003).
Zamostiano et al., “A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism,” Neuroscience Letters, vol. 264, 1999, pp. 9-12.
Brenneman et al., “Activity-Dependent Neurotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides1,” The Journal of Pharmacology and Experimental Therapeutics, vol. 285, No. 2, 1998, pp. 619-627.
Notice of References Cited in a U.S. Office Action dated Jan. 7, 2010, for related U.S. Appl. No. 11/578,141.
Aiso Sadakazu
Chiba Tomohiro
Kita Yoshiko
Matsuoka Masaaki
Nishimoto Ikuo
Birch Stewart Kolasch & Birch, LLP.
Kenzo Terashita
Massaaki Matsuoka
Sadakazu Also
Tomo Nishimoto
LandOfFree
Therapeutic agents of colivelin for neurodegenerative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents of colivelin for neurodegenerative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents of colivelin for neurodegenerative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4310519